Member Info for neilin62

Evening all.
Been doing a bit more digging.
Looking into Dr Keith Blundy's dealings.
Dr Blundy resigned from the BOD of Cizzle 2nd July 2019 - around the time we were engaged in the process of selecting a target for RTO. Could his resignation have been a condition of the RTO? Don't know, but the time scale seems to fit. Especially when you look at his other position. Turns out he is the CEO of Storm Therapeutics. Now, if you look at Storm Therapeutics work, it starts to get interesting.
They are backed by some of the biggest Pharma companies in the world.
1.Pfizer Venture Investments. As part of worldwide business development, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.
2. M Ventures (the strategic corporate venture capital arm of MERCK) Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas.
3. Seroba. Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech.
4. Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co. Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is looking at early stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas.
5. IP Group is a leading intellectual property commercialisation company
So the CEO that oversees these investments is none other than our previous director, so he knows exactly what Cizzle is worth to any one of these ventures.
All starting to look good from what i see.
I think that before too long we will see:
A) an announcement that we have entered into an agreement with a single CRO to manufacture the reagent (there are 2 that are being evaluated, and one will be chosen to proceed)
B) an announcement that we have entered into an agreement to license the intellectual property
Which will come first is anyone's guess.
Neil

AliCat71
That loss must be especially galling, since your husband worked for Photonstar, so presumably thought your investment was pretty safe.
If you look back at some of my previous posts, you would probably see it's clear where my sentiment lies, which may give you some comfort, but I will never advise anyone to buy/sell/hold any share, but i will offer my opinions for what they are worth.

Best regards
Neil

Hi Brotherhoodofbri,
Thank you for the response.
This is why i took 2 days and 4 sheets to do the sums!
Yes, the original numbers i was going on was the 261m figure but couldn't get it to square up as you say. It left a discrepancy of some 7m shares.
Then looking at the 253m figure, it did square up, but when i put in the figures as to AG's original holding, dilution etc, and then added in the warrants, the figures tied up again as to what is shown on Cizzle's website. (the puzzling thing then is that this figure states that it INCLUDES the warrants) so it is not at all clear. As you say there does appear to be some error somewhere.
To confuse matters further, i made a request to Hargreaves Lansdown for them to confirm the number of shares they are holding in nominee accounts. Under section 793, companies Act 2006, they cannot divulge this information, but can advise if they hold over, or under the 3% threshold. As of last night, they do not hold 4.66% as shown on the register, but less than the 3%
I think truth is, we don't really know, and will have to wait and see what is revealed in time, but at least the volatility seems to have eased.
Neil

PS, noted the below courtesy of Hardman & Co. Life Sciences Research technical report.

SNPs = Single nucleotide polymorphisms
Private company llumina agreed to acquire Grail in September 2020
This table should not be considered comprehensive. The large equipment and service providers, such as Illumina, LabCorp, Roche and Quest, have not been included in the table, as their activities in liquid biopsies and/or specialist tests are very small within their groups’ diverse operations. Where these companies come into play is in M&A. Smaller companies tend to take most of the risk in developing novel tests, but are approached once the technology is substantially de-risked and there is evidence of commercial success. These large players have the financial muscle and operational resources to commercialise the tests on a worldwide basis.
Any bets we get bought out when we prove up commercialisation?
Neil

2 days and 4 sheets of A4 paper later, i,m driving myself round the twist.
Here is what i have worked out.
1. AG has DEFINATELY taken up the warrants.
My reasoning is: His original holding was 1,966,244,949
After 500:1 consolidation = 3,932,490
The warrants are not subject to consolidation as they were granted at 3% of the company's enlarged share capital.
So that is 7,603,432. This amount is confirmed on the significant shareholders section of the company's website, as being included in the share issue of the company as at date of listing on Friday 14th.
The two combined add up to 11,535,922 so very close to the amount showing of 11,576,996, (allowing a discrepancy between prospectus and actual shares )
2. Can't confirm one way or the other as to if he has sold any, but i note Tra1's post tonight. Re reap2sow's comment, there is a very good reason he would sell now. That reason is the strike price of his warrants, against the current share price.
3. The 3 big trades on Monday of 3,584,773 & 3,600,000 & 3,114,773 share each represent an amount between 1.2% & 1.4%.
If these are any of the major shareholders listed, then they must issue a TR1 as each 1% threshold has been reached.
If they were from a single shareholder, then again it must be a TR1 .
If they were from one of the placing recipients, then that equates to approx 10.3million shares. Since they took 22million shares, then that is almost 50% of the entire placing. So to me, even if everyone of the placing investors sells, that is only a further 11million or so shares left, so 3 more big trades, and we are free of them. Again, if any of them took over 3%, it will show in a TR1, so watch out tomorrow to see if any appear.
Neil

108,342 @ 09:34 is showing as a sell.
It is a buy.
Neil

Did i have a stroke or have some posts been deleted?
Neil

Don't believe all the "sells" are sells.
They are struggling to keep up.
I can categorically tell you that my order for 106,951 still has not been filled from 08:00!
Neil

Mine is live on HL. Nice to see a value in there at last!
Good luck all.
Neil

Chriszzr
to correct a point earlier regarding Mr Glogowski's warrants.
The 3 years i stated was actually 3 years from the date of the option.
The period for exercising the warrants ends on successful admission to a trading market, so i would expect that he has already notified the BOD, and tthose warrants would be exercised at 08:00 tomorrow morning. Looking at the shares in issue, it appears that those shares have indeed been accounted for in the enlarged share capital.
Neil

Assuming you mean how many shares in CIZ, it is 261,051,15 ordinary shares.
Not included the deferred A shares as a result of the sub division, as they will never be listed.
Neil

12 hours and we are all on a new, long awaited journey.
Firstly, i must say DO NOT rely on anything i have said on here to make your investment choices I am not qualified to give financial advice, just my opinions.
Right, now that's out of the way.
As i said earlier, i won't be selling any time soon. What follows is just some of the reasons behind my stance.
1. We are in possibly THE best area of the bio tech sector.
2. There is a clear, immediate, unmet need for our technology.
3. We have an outstanding, world leading scientist in Dr Coverley.
4. Our competition are, i believe, in the realms of the detection of the PROGRESSION of cancer. They are desperate to crack the market of EARLY stage detection, but do not have the technology for a single biomarker. Dr Coverley HAS cracked it. They are in need our PATENTED C1Z1 technology.
5. The potential market is WORLDWIDE, with multiple revenue streams.
6. The placing was oversubscribed. We raised more than initially required.
7. Institutional investors are aboard.
8. We are fully funded for a program of development for the next 2 years.
9. Detection of lung cancer is only the first of our future products. Dr Coverley was asked if our technology could be extended to other cancers. Did you notice how candid she was about her answer? We have data suggesting that it is, and it is something we will be looking into.
10. We have the technology to SAVE LIVES.
11. We have the technology to save NHS / healthcare providers £MILLIONS
12. Our BOD are already in discussions with various entities. I am sure that someone will be talking to NHS to get hospital lab validation for our product.
I could go on. but don't want to sound like i am one of those rampers.
One final thought and again, this is only my own opinion, ..... we get this right, and i truly believe that given time, this will be one of those rare phenomenons. Another Novacyt in the making.
6.5pence to almost £12 a share within 12 months. I,m not saying we will be the same, but the potential is there.
No, my shares are most definately not for sale.
Neil

Hi chriszzr
No he has not yet. There is a time limit but i,m not sure offhand what the period is. I seem to recall it is normally within 3 years from admission.
The info is not in any way privileged, and is all in the pubic domain.
Neil

No names will be disclosed as none of the subscribers breached the 3% public disclosure requirement (TRA1), BUT Institutional investors WERE involved.
Neil

Upshunt
If you have 7m shares in Bou, you will have 14,000 new shares in Cizzle (500:1 consolidation)

It probably won't come as a great surprise to most on here, but i will not be selling my shares any time soon. I will post something further later tonight when i get home.
Neil

Following the passing of the Resolutions the Company can confirm, inter alia, that the acquisition of Cizzle Biotechnology Technology Limited and proposed Placing has been completed, the Share Reorganisation is effective, application will be made for the Company's name to be changed to Cizzle Biotechnology Holdings Plc and the Company's Enlarged Share Capital will be admitted to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange. Trading in the Company's shares is expected to begin at 8.00 a.m. on 14 May 2021 under the ticker CIZ.
Neil

Hi Dinoman
Honest answer is, i'm not sure, having never had to do it, and it may be worth checking with your broker as they have different stances on Bed & ISA
You can't sell as BOU as they won't exist from 6pm tonight. But yes, i think the only way to get them back into an ISA is to sell and buy back. Some providers do this in a matter of minutes, and you may only lose a few shares. Other take 3 days or more.
Neil

McFish2020
Look at Bould Opportunities website, under "investors" section, then publications/circulars
We will relist as CIZ
Neil

nightye1
i believe the 80% discount is the way that a company is valued. As Allan says, the external companies used a number of models to determine the value. One of the usual models is "discounted cash flow". This is where a value is determined by projection of future cash revenue, but then discounted as it is based on future value, not today's actual value. (as we haven't achieved those revenues yet) In our case, we are also seen as an early stage company, so the discount levied has been determined as 80%. You could look at it another way and see it as a big potential uplift in the share price.
Couple of further things i have gleaned from the information out there.....
The BOD are already in discussions with manufacturers for the reagents.
There is keen interest from institutional investors, which supports the thought that i made previously as to us coming off AIM and listing on main market. Watch this space in the future.
Allan has been talking to high level the Chinese Minister for Health.
We don't have to wait for CE mark /FDA approval to license the technology to other companies., and i expect to see licensing deals being confirmed very shortly with licensing partners, manufacturers and development partners.
I would also take a bet that we will shortly find that we have re-entered into an agreement with a certain Chinese CRO.
SO, friday's share price will be interesting, but the long term is going to be something else!
I said before time is the key factor here, and, IN MY OPINION ONLY, so do your own research,
For those that invested in a certain company i mentioned a few months back, CONGRATULATIONS. If you haven't already seen it, read the RNS issued tonight after trading hours. It just shows that when it all looks lost, dreams can come true.
Neil

Well i guess this is Allan Syms reason for talking to China.
Extracts taken from Hindawi BioMed Research International

[1]. Lung cancer is not only the most common cancer in the world, but also the primary reason for death due to cancer [1]. At present, the number of Chinese patients who were newly diagnosed with lung cancer is about 500 thousand each year, and the number is expected to reach one million by 2025

[3]. Currently, the most often used treatments for NSCLC are surgery, radiotherapy, and chemotherapy, in which the complete surgical resection is the most effective method [4]. Despite the improvements of surgical techniques and instruments in recent years, the overall 5-year survival rate for NSCLC patients after surgery is from 15% to 45% [6]. On the other hand, most patients that were diagnosed with NSCLC were already in the unresectable stage of IIIB or IV and the option of surgery treatment was not feasible, which is the main reason why the overall 5-year survival rate of NSCLC patients is only 12%. However, the overall 5-year survival rate can be increased to 50% if patients can be diagnosed in an early stage

[6]. Currently, the diagnosis of NSCLC mainly depends on X-ray, CT, sputum cytology, fiber bronchoscopy, and cellular pathology. However, X-ray is not sensitive to small lesions and covert lesions; sputum cytology only works on lung cancer originated in the center of airways and has a low detection rate; fiber bronchoscopy is not suitable for early diagnosis due to its invasiveness; cellular pathology cannot precisely determine malignance stages [7]. As such, identifying molecular biomarkers for early diagnosis of NSCLC is urgently needed.

Literature review of the top predicted gene biomarkers suggested that most of them were already considered critical for development of NSCLC.

CIZZLE has the technology to help lung cancer sufferers by increasing the 5 year survival rate by 400% !!!
Neil